Banner panic 2020

Bruker at WCB - Virtual Event

Bruker is excited to be a part of this year's virtual Well Characterized Biologics & Biological Assays conference. We hope you can join us at this year's event and are able to participate in our workshop and poster session. See below for additional details.

Workshop: Measuring Protein Concentration by Diffusion-filtered Quantitative Nuclear Magnetic Resonance Spectroscopy

Date/time: Wednesday, Oct 28: 10:30 am - 10:50 am (EST), Live Q&A Session: Wednesday, Oct 28:12:30pm - 1pm (EST)

Presenter: Scott Bradley, Principal Research Scientist - Eli Lilly and Company

Summary

Protein concentration is a crucial property for many areas of research. However, none of the previously reported methods for measuring protein concentration measure an intrinsic property of the molecule that is known a priori. This presentation will discuss (1) a diffusion-filtered qNMR experiment (DF-qNMR) for quantitating proteins in therapeutic formulations and (2) an overall method for measuring absolute protein concentration based on this DF-qNMR experiment. Results of the method, which is referred to as VILMHA (valine isoleucine leucine methyl hydrogen analysis), will be presented for several proteins.

Scott Bradley Photo

Dr. Scott Bradley
Principal Research Scientist - Eli Lilly and Company

Poster Presentation: Analysis of Biologics and Biosimilars by Magnetic Resonance

Date/time: On-Demand

Presenter: Anna Codina, Director Pharmaceutical Business Unit - Bruker BioSpin

Summary

High-resolution NMR is a key technology that provides critical information about protein structure and dynamics. Recent advances in acquisition and analysis now allow us to see intact antibodies at natural abundance. NMR is especially sensitive to changes to higher order structure at atomic resolution, making it ideally suited for similarity assessment of biologics and biosimilars. NMR also allows for intact protein analysis, enabling evaluation of the structure of therapeutic drugs without modification, in conditions that are physiologically relevant. Because of its intrinsically high information content NMR has the potential to reduce the number of techniques needed to characterize therapeutic drugs. In this poster presentation, current applications of magnetic resonance (NMR, EPR, TD-NMR) for the analysis of biotherapeutic drugs will be reviewed.

Portraits Bruker Anna Codina headshot

Dr. Anna Codina
Director, Pharmaceutical Business Unit

WCB 2020